Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Jurado M, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2002;8(3):161-9. doi: 10.1053/bbmt.2002.v8.pm11939606. Biol Blood Marrow Transplant. 2002. PMID: 11939606 Free article. Clinical Trial.
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
Furlong T, Leisenring W, Storb R, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K, Kiem HP, Nash RA, Sanders JE, Witherspoon R, Thompson D, Martin PJ. Furlong T, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2002;8(4):206-12. doi: 10.1053/bbmt.2002.v8.pm12014809. Biol Blood Marrow Transplant. 2002. PMID: 12014809 Free article.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Deeg HJ, et al. Among authors: anasetti c. Blood. 2002 Aug 15;100(4):1201-7. doi: 10.1182/blood-2002-02-0527. Blood. 2002. PMID: 12149198 Free article. Clinical Trial.
Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR. Deeg HJ, et al. Among authors: anasetti c. Blood. 2003 Dec 1;102(12):3912-8. doi: 10.1182/blood-2003-06-1856. Epub 2003 Aug 14. Blood. 2003. PMID: 12920019 Free article. Clinical Trial.
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, Hansen JA, Nash RA, Petersdorf EW, Storb R, Ghetie V, Schindler J, Vitetta ES. Martin PJ, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2004 Aug;10(8):552-60. doi: 10.1016/j.bbmt.2004.04.002. Biol Blood Marrow Transplant. 2004. PMID: 15282533 Free article. Clinical Trial.
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R. Nash RA, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505. doi: 10.1016/j.bbmt.2005.03.006. Biol Blood Marrow Transplant. 2005. PMID: 15983549 Free article. Clinical Trial.
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Deeg HJ, et al. Among authors: anasetti c. Biol Blood Marrow Transplant. 2006 May;12(5):573-84. doi: 10.1016/j.bbmt.2005.12.036. Biol Blood Marrow Transplant. 2006. PMID: 16635793 Free article. Clinical Trial.
440 results